Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.

Fabrizio FabriziFederica TripodiRoberta CeruttiLuca NardelliCarlo M AlfieriMaria F DonatoGiuseppe Castellano

Published in: Viruses (2022)

Pan-genotypic combinations, such as GLE/PIB and SOF/VEL, appear effective and safe for HCV in advanced CKD, even if a limited number of studies with small sample sizes currently exist on this issue. Studies are under way to assess whether successful antiviral therapy with DAAs will translate into better survival in patients with advanced CKD.

Keyphrases

hepatitis c virus
chronic kidney disease
case control
human immunodeficiency virus
healthcare
health information
computed tomography
mesenchymal stem cells
social media